Antenatal breastmilk expression for women with diabetes in pregnancy - a feasibility study.
Antenatal period
Breastfeeding
Diabetes
Expressed breast milk
Hypoglycemia
Infant
Newborn
Pregnancy
women’s experience
women’s satisfaction
Journal
International breastfeeding journal
ISSN: 1746-4358
Titre abrégé: Int Breastfeed J
Pays: England
ID NLM: 101251562
Informations de publication
Date de publication:
23 07 2021
23 07 2021
Historique:
received:
20
10
2020
accepted:
08
06
2021
entrez:
24
7
2021
pubmed:
25
7
2021
medline:
26
10
2021
Statut:
epublish
Résumé
Mothers with diabetes are less likely to achieve successful breastfeeding. Antenatal breastmilk expression (ABE) may facilitate earlier breastfeeding, but feasibility of introducing ABE and its acceptance among Scandinavian women have previously not been investigated. This observational trial was conducted between the 1 January 2019 and the 12 March 2020 in Tromsø, Norway. We aimed to determine the feasibility of ABE in terms of practicality and acceptability among women with medically (metformin or insulin) treated diabetes. Women were invited to participate during antenatal visits from 32 weeks gestation. Participants received instruction and started ABE from gestation week 37 + 0. Participants, and their infants, were followed until 6-8 weeks after birth. We collected data on breastfeeding rates, infant hypoglycemia, transfer to the neonatal unit, and the women's overall experience and satisfaction with antenatal breastmilk expression. Twenty-eight of 34 (82%) invited women consented to participate. All started ABE from week 37 + 0, and continued until hospital admission. No women reported any discomfort or side effects. Labor was induced at 38 weeks gestation. Twenty-four women brought harvested colostrum to the maternity ward, which was given to their infants during the first 24 h of life. Breastfeeding rates at discharge were 24/28 (86%) and 21/27 (78%) at 6-8 weeks after delivery. Seven (25%) infants were transferred to the neonatal unit; four because of hypoglycemia. Maternal satisfaction assessed 6-8 weeks after delivery revealed that all participants felt positive about the ABE, but one woman would not recommend it to other pregnant women. Implementing a structured ABE guideline for women with medically treated diabetes was feasible. The intervention was associated with high level of satisfaction among study participants. No obvious side effects were observed, and breastfeeding rates at discharge and 6-8 weeks after delivery were higher than in comparable studies. The study was registered at the research study registry at the University Hospital of North Norway ( Nr 2018/7181 ).
Sections du résumé
BACKGROUND
Mothers with diabetes are less likely to achieve successful breastfeeding. Antenatal breastmilk expression (ABE) may facilitate earlier breastfeeding, but feasibility of introducing ABE and its acceptance among Scandinavian women have previously not been investigated.
METHODS
This observational trial was conducted between the 1 January 2019 and the 12 March 2020 in Tromsø, Norway. We aimed to determine the feasibility of ABE in terms of practicality and acceptability among women with medically (metformin or insulin) treated diabetes. Women were invited to participate during antenatal visits from 32 weeks gestation. Participants received instruction and started ABE from gestation week 37 + 0. Participants, and their infants, were followed until 6-8 weeks after birth. We collected data on breastfeeding rates, infant hypoglycemia, transfer to the neonatal unit, and the women's overall experience and satisfaction with antenatal breastmilk expression.
RESULTS
Twenty-eight of 34 (82%) invited women consented to participate. All started ABE from week 37 + 0, and continued until hospital admission. No women reported any discomfort or side effects. Labor was induced at 38 weeks gestation. Twenty-four women brought harvested colostrum to the maternity ward, which was given to their infants during the first 24 h of life. Breastfeeding rates at discharge were 24/28 (86%) and 21/27 (78%) at 6-8 weeks after delivery. Seven (25%) infants were transferred to the neonatal unit; four because of hypoglycemia. Maternal satisfaction assessed 6-8 weeks after delivery revealed that all participants felt positive about the ABE, but one woman would not recommend it to other pregnant women.
CONCLUSIONS
Implementing a structured ABE guideline for women with medically treated diabetes was feasible. The intervention was associated with high level of satisfaction among study participants. No obvious side effects were observed, and breastfeeding rates at discharge and 6-8 weeks after delivery were higher than in comparable studies.
TRIAL REGISTRATION
The study was registered at the research study registry at the University Hospital of North Norway ( Nr 2018/7181 ).
Identifiants
pubmed: 34301285
doi: 10.1186/s13006-021-00393-1
pii: 10.1186/s13006-021-00393-1
pmc: PMC8299162
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
56Informations de copyright
© 2021. The Author(s).
Références
J Perinat Educ. 2005 Summer;14(3):23-32
pubmed: 17273439
PLoS One. 2018 Feb 15;13(2):e0192757
pubmed: 29447299
Diabet Med. 2016 Jan;33(1):17-24
pubmed: 26113051
Nature. 1992 Apr 9;356(6369):526-9
pubmed: 1313946
Can J Public Health. 2013 Sep 12;104(5):e388-93
pubmed: 24183179
Aust N Z J Obstet Gynaecol. 2019 Dec;59(6):811-818
pubmed: 30891743
Obes Rev. 2015 Aug;16(8):621-38
pubmed: 26016557
Reprod Health. 2018 Apr 4;15(1):58
pubmed: 29618359
Diabet Med. 2013 Sep;30(9):1094-101
pubmed: 23692476
BMJ Open. 2019 Jan 3;9(1):e021513
pubmed: 30610018
BMC Pregnancy Childbirth. 2017 Nov 8;17(Suppl 2):352
pubmed: 29143677
Int Breastfeed J. 2012 Dec 01;7(1):18
pubmed: 23199299
J Clin Epidemiol. 2014 Mar;67(3):267-77
pubmed: 24275499
Am J Obstet Gynecol. 1993 Feb;168(2):514-9
pubmed: 8438920
Breastfeed Med. 2014 Apr;9(3):157-60
pubmed: 24160359
Diabetologia. 2020 Dec;63(12):2571-2581
pubmed: 32910247
Lancet. 2017 Jun 3;389(10085):2204-2213
pubmed: 28589894
Can J Diabetes. 2018 Apr;42 Suppl 1:S255-S282
pubmed: 29650105
BJOG. 2011 Apr;118(5):578-88
pubmed: 21265999